



Participants:

Pr. Arne Ljungqvist, Chairman	Attending
Pr. Eduardo De Rose	Attending
Pr. Kenneth Fitch	Attending
Pr. Theodore Friedmann	Attending
Pr. David Gerrard	Attending
Dr. Bjorn Hedman	Attending
Pr. Luis Horta	Attending
Pr. Ichiro Kono	Attending
Dr. Jean-Claude Mbanya	Attending
Dr. Babette Pluim	Attending
Dr. Patrick Schamasch	Attending
Pr. Carlos Hamilton	Apologies

WADA Staff

Dr Alain Garnier	Attending
Dr Irene Mazzoni	Attending
Dr Olivier Rabin	Attending

1. Welcome

- Words of welcome by Richard W. Pound and Arne Ljungqvist.

2. Review of agenda

- Agenda approved.

3. Review of 2006 Prohibited List and recommendation to ExCo

- The 2006 Draft of the Prohibited List prepared by the List Committee is presented by Olivier Rabin.
- All changes included in the Draft of the 2006 Prohibited List are accepted by the HM&R Committee.
- In addition to the changes made by the List Committee, two other modifications are included by the HM & R Committee as follows:
 - tibolone, a synthetic steroid with anabolic properties used to treat post-menopausal symptoms, is added to the examples of Other Anabolic Agents.
 - methylphenidate is removed from the specified list and included in the Out-of-competition Monitoring Program, as it is a prescription drug not generally available and so deemed to not to be susceptible to unintentional use.
- Some topics are subjected to more detailed discussions:
 - T/E ratio: it is apparent that for several stakeholders who forwarded their comments on the List, that the rationale for changing the threshold from 6 to 4 is still not clear. It is agreed that a more detailed explanation will be given to answer their concerns when necessary.
 - Cannabinoids: the threshold of 15 ng/mL for passive inhalation is reaffirmed based on scientific literature.

Deleted: 3/6/2006

DRAFT

- Glucocorticosteroids: ongoing research projects are aimed to better define the threshold for adverse analytical findings.
- Monitoring Program: It is agreed to continue monitoring the substances already in the program and to reassess the statistics since 1995 onwards (IOC + WADA) for caffeine and pseudoephedrine to increase the data.
- Draft of 2006 Prohibited List is adopted for proposal to WADA Executive Committee (appendix 1).

4. Review and recommendation for the 2005 research projects

- Members of the HM&R Committee responsible for organizing the peer review process and WADA staff present a summary of the evaluations received in their field.
- A ranking of projects within each category is made, and 22 projects are selected (see appendix 2).
- For several projects, budgetary revisions are recommended.
- For two projects, coupling or sharing experiments between research teams is recommended.
- It is agreed that the letters of rejections will contain a summary of the main criticisms by reviewers, to allow the researchers better understand why the grant was not accepted.
- A summary of the Progress and Final reports of ongoing and future funded projects will be forwarded to the HM & R Committee members for their information.

5. Hypoxic chamber update

- The performance-enhancing capacities and their potential health risk of hypoxic chambers are discussed, based on the recommendations by the List Committee and the literature and information available to date. It is agreed that it is a performance-enhancing method that appears not to be a health risk if monitored by a physician and used as directed. The conclusions of WADA's independent Ethics Review Panel are expected to be shared with the HM & R Committee.

6. Report from TUE Subcommittee

- The need to write a harmonized Medical Guidelines document for the granting of TUE is stressed and it is decided that WADA office and TUE Committee should have the responsibility to prepare and update those guidelines as needed.

7. Report from Laboratory Subcommittee

- An update on laboratories in pre-accreditation (Salt Lake City and New Delhi) is presented by Prof. Horta.

8. Update on Dietary Supplement Symposium

- An update on the Dietary Supplement Symposium to take place in September 2005 is presented by Casey Wade.

9. Update on Gene Doping Symposium

- It is confirmed that the 2nd Symposium on Gene Doping, co-organized by WADA, the Swedish Sports Confederation and the Karolinska Institute, will take place at Nobel Forum, Karolinska Institute in Stockholm on December 4th-6th 2005.

10. WADA's presence in Scientific Meetings

- HM & R members should be ready to represent the Committee at scientific meetings and deliver WADA's message.

11. Other matters

- With reference to the status of limitations of 8 years for sample testing, as established by the Code, discussions and suggestions on sample storage, collection and analysis are considered for further discussion in the future.
- Ken Fitch informs that he will be leaving the HM & R Committee.

Deleted: 3/6/2006

DRAFT

12. Next meeting

- It is confirmed that the HM&R Committee meeting will take place only once a year in the month of September for a two-day period, while the subcommittees will meet more frequently during the year.

Appendices

Appendix 1: the 2006 Prohibited List, as published on September 2005.

Appendix 2: table of recommended research projects for 2005.

CONFIDENTIAL

Deleted: 3/6/2006